Literature DB >> 2109978

Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin.

A Bzowska1, E Kulikowska, D Shugar.   

Abstract

Purine nucleoside phosphorylase (PNP), from calf spleen, human erythrocytes and E. coli have been examined with regard to structural requirements of substrates and inhibitors. Kinetic parameters (Km, Vmax/Km) for a variety of N(1) and/or N(7)-methylated analogues of guanosine, inosine and adenosine have been evaluated for all three enzymes. The substrate and/or inhibitor properties of purine riboside, 1,6-dihydropurine riboside, some deazapurine nucleosides: 3-deaza- and 7-deazainosine, 1,3-dideazapurine riboside (ribobenzimidazole), and a variety of acyclonucleosides, have been determined with mammalian and bacterial enzymes. Overall results indicate distinct similarities of kinetic properties and structural requirements of the two mammalian enzymes, although there are some differences as well. The N(1) and O6 of the purine ring are necessary for substrate-inhibitor activity and constitute a binding site for the mammalian (but not the bacterial) enzymes. Moreover, nucleosides lacking the N(3) undergo phosphorolysis and those lacking N(7) are inhibitors (but not substrates). Methylation of the ring N(7) leads to two overlapping effects: labilization of the glycosidic bond, and impediment to protonation at this site by the enzyme, a postulated prerequisite for enzymatic phosphorolysis. It is proposed that a histidine interacts with N(1) as a donor and O6 as an acceptor. Alternatively N(1)-H and C(2)-NH2 may serve as donors for hydrogen bonds with a glutamate residue. The less specific E. coli enzyme phosphorolyses all purine ring modified nucleosides but 7-deazainosine which is only an inhibitor. On the other hand, the bacterial enzyme exhibits decreased activity towards N(7)-methylated nucleosides and lack of affinity for a majority of the tested acyclonucleoside inhibitors of the mammalian enzymes. The foregoing results underline the fundamental differences between mammalian and bacterial enzymes, including variations in the binding sites for the purine ring.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109978     DOI: 10.1515/znc-1990-1-211

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  15 in total

1.  Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.

Authors:  S E Ealick; Y S Babu; C E Bugg; M D Erion; W C Guida; J A Montgomery; J A Secrist
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Femtosecond dynamics coupled to chemical barrier crossing in a Born-Oppenheimer enzyme.

Authors:  Rafael G Silva; Andrew S Murkin; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 3.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

4.  Crystal structure of Escherichia coli purine nucleoside phosphorylase in complex with 7-deazahypoxanthine.

Authors:  Vladimir I Timofeev; Nadezhda E Zhukhlistova; Yuliya A Abramchik; Ilya I Fateev; Maria A Kostromina; Tatiana I Muravieva; Roman S Esipov; Inna P Kuranova
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-05-23       Impact factor: 1.056

5.  Structure of grouper iridovirus purine nucleoside phosphorylase.

Authors:  You-Na Kang; Yang Zhang; Paula W Allan; William B Parker; Jing-Wen Ting; Chi-Yao Chang; Steven E Ealick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

6.  Synthesis of Fluorine-Containing Analogues of Purine Deoxynucleosides: Optimization of Enzymatic Transglycosylation Conditions.

Authors:  M S Drenichev; E O Dorinova; I V Varizhuk; V E Oslovsky; M A Varga; R S Esipov; D D Lykoshin; C S Alexeev
Journal:  Dokl Biochem Biophys       Date:  2022-05-10       Impact factor: 0.834

7.  Isotope-specific and amino acid-specific heavy atom substitutions alter barrier crossing in human purine nucleoside phosphorylase.

Authors:  Javier Suarez; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

8.  New trends in nucleoside biotechnology.

Authors:  I A Mikhailopulo; A I Miroshnikov
Journal:  Acta Naturae       Date:  2010-07       Impact factor: 1.845

9.  Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

Authors:  Preetinder P Singh; Swapna Joshi; Pamela J Russell; Sham Nair; Aparajita Khatri
Journal:  BMC Cancer       Date:  2011-08-24       Impact factor: 4.430

10.  A QM-MD simulation approach to the analysis of FRET processes in (bio)molecular systems. A case study: complexes of E. coli purine nucleoside phosphorylase and its mutants with formycin A.

Authors:  M Sobieraj; K A Krzyśko; A Jarmuła; M W Kalinowski; B Lesyng; M Prokopowicz; J Cieśla; A Gojdź; B Kierdaszuk
Journal:  J Mol Model       Date:  2015-03-10       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.